Human telomerase reverse transcriptase (hTERT) is the catalytic component of a functional telomerase complex, which is important in maintaining cell immortality. In most normal human adult cells, the expression of telomerase is very low and/or transient. In contrast, almost 90% of human tumors express a relatively high level of telomerase implying the possibility of using hTERT as a universal candidate tumor antigen. In this study, we show that human monocyte-derived dendritic cells (DCs) lack telomerase activity. Similar to other normal somatic cells, DCs express the RNA (hTR) component but not the catalytic component, hTERT. We also show that telomerase activity could be reconstituted using either lipid-mediated transfection of the hTERT plasmid DNA or transduction with an E1-, E3-deleted adenoviral vector containing the hTERT gene. However, relative to plasmid transfection, adenoviral gene transfer produced higher levels of hTERT expression. Nine of 10 AdhTERT-transduced DCs were able to generate CTL responses, while only three of nine plasmid-transfected DCs did. CTLs primed against hTERT exhibited killing of telomerase positive but not telomerase negative tumor lines of diverse tissue origins. Antigenic specificity of these T cells to telomerase was further determined by introducing hTERT gene into a telomerase negative cell line, U2OS, by adenoviral transduction. Although some antigenic specificity was directed against adenoviral epitopes, the majority of CTLs were targeted against telomerase-derived antigen(s). Thus, the hTERT gene, particularly as delivered via the recombinant adenovirus, may be useful as vaccine to induce specific T-cell-mediated tumor immunity in cancer patients. In addition, our results suggest that telomerase activity and/or telomerase expression after hTERT gene transfer have a predictive value in the success of hTERT/DC-based cancer vaccination.
G eneration of antigen-specific cytotoxic T-cell (CTL)
responses is a central tenet of cancer immunotherapy. Tumor-antigen-specific CTLs have been shown to be effective in mounting an antitumor response both in vitro and in vivo. [1] [2] [3] [4] Extensive research on the identification of neo-antigens on tumor cells has largely been restricted to certain types of tumors, most notably to melanoma.
1,2 A great majority of the antigens that are highly expressed on tumor cells have also been found on normal cells, albeit to a lesser extent. Moreover, the tumor-associated antigens (TAA) identified so far are usually specific to a particular tumor type and found only in a subset of tumor patients. Identification of a universal tumor antigen would have obvious significant impact on the application of cancer immunotherapy.
Human telomerase reverse transcriptase (hTERT) is a ribonucleoprotein complex responsible for the addition of T 2 AG 3 repeats to the telomere ends of chromosomes. 5, 6 The telomerase protein shares homology with viral reverse transcriptases and, in addition, contains unique motifs that are conserved across different species. In normal human somatic cells where there is no or little telomerase activity, telomere length progressively declines during cellular division resulting in critical shortening of telomeres. The attrition of telomeric ends has been causally linked to replicative senescence and irreversible growth arrest of cultured cells. [7] [8] [9] We have previously shown that exogenous hTERT gene delivery to cultured human cells of different types confers immortality but not tumorigenicity. [10] [11] [12] On the other hand, greater than 90% of human tumors of different pathology and origins have been shown to upregulate telomerase expression that is necessary for maintaining immortality of the tumor cells. 13 The widespread expression of telomerase in tumors indicates that peptide fragments of hTERT could serve as tumor specific antigen(s) and this has been confirmed in several reports. Vonderheide et al 14 demonstrated that an HLA-A2-restricted telomerase peptide could be recognized as a tumor antigen by cytotoxic T lymphocytes. Subsequently, Minev et al 15 generated CTL responses in vitro using hTERT peptides against telomerase-positive tumors from normal healthy donors and from cancer patients. Recently in collaboration with Eli Gilboa and colleagues, we have demonstrated that mice vaccinated with telomerase (hTERT) RNA-loaded dendritic cells (DCs) exhibited significant protection against tumor challenge. 16 More importantly, telomerase-specific CTLs generated in vitro from cancer patients using similar method were able to lyse autologous tumor cell targets.
DCs are powerful antigen-presenting cells (APC) in the generation of a primary immune response against a variety of tumor antigens. [17] [18] [19] These cells express high levels of MHC class I and class II antigens along with several different costimulatory molecules, which are crucial to potentiate an effective antigen-specific T-cell response. Different methods have been developed to introduce TAAs to bone marrow or monocyte-derived DCs in order to induce CTL responses against tumor cells. Initially, peptide fragments or proteins were used to pulse DCs to generate antitumor immunity. [20] [21] [22] [23] [24] Subsequently, genetic modification of DCs by adenoviral transduction [25] [26] [27] [28] [29] or by liposome-mediated transfection of tumor-specific genes using DNA or RNA complexed with liposome have been shown to be effective in cancer vaccination. [30] [31] [32] [33] [34] [35] [36] [37] The latter approaches eliminate the necessity of identifying and characterizing MHC class-I restricted peptides specific for different haplotypes. Thus, TAA-modified DCs through ex vivo or in vivo manipulation are attractive candidates for cancer immunotherapy. [38] [39] [40] In this report, we show that human monocytederived DCs express the RNA component (hTR) of the telomerase complex, but do not express the gene encoding for the catalytic subunit. Telomerase activity, however, can be reconstituted when DCs are transfected with hTERT plasmid DNA liposome complex or by AdhTERT transduction. The hTERT gene-modified DCs are capable of generating a specific CTL response against various hTERT-expressing cancer cell lines. The susceptibility of tumor cell lines of various origins to lysis by telomerase-specific CTLs suggests that hTERT could be used either alone or in combination with other tumor antigens in immunotherapy against a wide range of cancers.
Materials and methods
Phenotypic analysis and purification of peripheral blood mononuclear cells (PBMC) derived dendritic cells PBMC were isolated from healthy HLA-A2 + donors' buffy coats by Ficoll-Hypaque density gradient centrifugation. DCs were generated from PBMC in the presence of GM-CSF and IL-4 (both were purchased from R&D Systems, Minneapolis, MN). 41 PBMC (1 Â 10 8 ) were seeded into T150 culture flasks in AIM-V medium (Life Technologies, Grand Island, NY). After monocytes were adhered (incubation for 2 hours), the nonadherent cells were removed and frozen in freezing media (60% AIM-V, 30% fetal bovine serum (FBS), 10% dimethylsulfoxide (DMSO)) for later use in CTL assays. The adherent cells were cultured for 7 days in AIM-V containing 10 ng/ml human recombinant GM-CSF (10 ng/ml, R&D Systems Inc., Minneapolis, MN) and IL-4 (10 ng/ml, R&D Systems). DCs were harvested on the seventh day of culture. Cell surface markers were analyzed by immunostaining and flow cytometry. For immunophenotyping we used the following antibodies: CD14; HLA-DR; CD11c; CD3; CD19 (all from Becton Dickinson, San Jose, CA); and CD86 (PharMingen, San Diego, CA); CD56 (Coulter-Immunotech, South San Francisco, CA). Cells (5 Â 10 5 ) were incubated with antibody for 30 minutes on ice, then washed with phosphate-buffered saline (PBS) and fixed with 1% paraformaldehyde in PBS. Enrichment of the DC population for reverse transcriptase (RT)-PCR and TRAP analysis was performed by negative selection using anti-CD3 and anti-CD19 magnetic beads according to the manufacturer's instructions (Miltenyi Biotec, Bergisch Gladbach, Germany). Flow cytometric analysis was performed on the FACScan flow cytometer (Becton Dickinson) using CELLQuest program (Becton Dickinson).
Tumor cell lines
Tumor cell lines used as targets in CTL assays included 143B, U2OS (human osteosarcoma lines); MEL624, (human melanoma line), SW403, SW1417 (human colorectal adenocarcinoma). MEL624 cell line was a kind gift from Dr Jeffery Weber (USC, Los Angeles, CA) and all other cell lines were obtained from American Type Culture Collection (ATCC, Manassas, VA). With the exception of SW1417, all other cell lines were determined to be HLA-A2 positive.
Telomeric repeat amplification protocol (TRAP) assay
A standard TRAP assay was used to measure the telomerase activity in unmodified and hTERT genemodified DCs. For visualizing the DNA ladder, 1000 and 5000 cell equivalents were analyzed. Quantitation of telomerase activity was performed as described previously 42 by calculating the total product generated (TPG) compared to the 293 cells, used as positive control.
RT-PCR analysis for hTR and hTERT
The primers for RT-PCR were as follows: (1) 
Plasmid DNA and recombinant adenovirus vectors
Construction of pGRN145, a plasmid vector encoding hTERT downstream of the myeloproliferative sarcoma virus (MPSV) promoter, has been previously described, 11 pBBS 212 plasmid DNA lacking the hTERT sequence was used as a negative control for all transfection experiments.
AdhTERT is a replication-deficient, E1-and E3-deleted, recombinant-adenovirus-5-based vector containing a cassette encoding the human telomerase gene under the control of CAG (cytomegalovirus (CMV) enhancer + chicken b-actin promoter + a portion of 3 0 untranslated region of rabbit b-globin gene) promoter. The AdhTERT virus was generated by COS-TPC method 43, 44 using the Adenovirus Expression Vector Kit from Takara Biomedicals (Tokyo, Japan). Briefly, the 3419 bp hTERT fragment was cloned into SwaI site in pAxC wt cosmid (Takara Biomedicals, Tokyo, Japan) and transfected into 293 cells. The desired recombinant adenovirus was generated by homologous recombination in 293 cells. After several rounds of plaque purification, the rAdh-TERT viruses were amplified in 293 cells and purified by CsCl density gradient ultracentrifugation. Viral particle concentration was determined by measuring the optical density at A260 and the infectious titer was determined by standard plaque assay. A second recombinant, E1-, E3-deleted Ad-5 virus carrying the green fluorescent protein (GFP) under the control of CMV immediate-early promoter/enhancer was obtained from Q-Biogene (Montreal, Canada), and was used as a control vector for DC transduction.
Transfection of DC in vitro
DCs were transfected by DNA/cationic lipid complexes. DOTAP Liposomal Transfection Reagent (Boehringer Mannheim, Germany) was used as the cationic lipid. DOTAP and hTERT DNA were mixed together at a ratio of 2:1 in 200 ml of PBS and incubated for 25 minutes at room temperature (RT). Then 3-5 ml of AIM-V medium with IL-4 and GM-CSF (no serum) was added to the tubes with the DOTAP-DNA mixture. The medium containing DOTAP complexed with DNA was then added to the cells and incubated for 4 hours. Next, DOTAP-containing medium was replaced with fresh AIM-V medium. At 96 hours after transfection, a portion of the cells was used to stimulate autologous T cells. Aliquots of the remaining transfected DC were frozen for subsequent restimulation of T cells.
AdhTERT transduction of DC
DCs were plated into T25 flasks in culture medium at a concentration not exceeding 5 Â 10 6 cells per flask and allowed to adhere for 2 hours at 371C. AdhTERT virus or AdGFP was added to each flask at different MOIs and incubated in a minimal volume of media for 4 hours. Cells were then fed with AIM-V medium and harvested 3 days later for CTL stimulation or immunofluorescence analysis.
Immunofluorescence staining of DC with hTERT antibody
The mouse anti-hTERT peptide monoclonal antibody, KM-2311, was obtained from Kyowa Hakko Corporation (Tokyo, Japan). The antibody was raised against a Cterminal peptide fragment of the human telomerase subunit (residues 1119-1132). The antibody has been shown to recognize the 126 kDa enzymatic subunit of the telomerase complex by Western blot analysis (J Trager and R Pruzon, unpublished observation).
Cells were grown in six-well culture dishes, fixed with 3.7% paraformaldehyde for 7 minutes at RT. They were then washed with buffer containing 0.1 M Tris pH 7.5, 1.5 M NaCl, 1% BSA, and permeabilized in the presence of 2% Triton X-100 (Sigma, St Louis, MO). Next, cells were incubated with the primary hTERT antibody (0.5 mg/ml) for 1 hour at RT, washed, and further incubated with secondary biotinylated anti-mouse antibody (Vector Laboratories, Burlingame, CA). Finally, the cells were incubated with an appropriate concentration of Streptavidin Texas Red (Vector Laboratories), washed twice, and preserved with Vectashield (Vector Laboratories). For inhibition studies, the antibody was incubated overnight at 41C with 1 mg of the telomerase peptide and the mixture was added to the DCs for staining.
Generation of hTERT-specific CTL
At 96 hours after transfection with hTERT and control plasmid DNAs or 72 hours after infection with AdhTERT or AdGFP viruses, two-thirds of DCs were frozen for future T-cell stimulations and one-third of DCs were combined with autologous T cells at a ratio of 1:7. For T-cell culture, AIM-V medium with hIL-2 (48 U/ml), hIL-7 (10 ng/ml, R&D Systems), and heat-inactivated Human AB serum (10%) were used. CTL cultures were stimulated twice with hTERT transduced DCs at the same ratio. Prior to the third stimulation, CD8 + T cells were enriched by negative selection using anti-CD4 and anti-CD56 magnetic beads (Miltenyi Biotec). The purity of CD8+ -enriched population was checked by immunophenotypic analysis of T cells before and after purification.
Chromium release assays
CTL as effector cells were used 5 days after the third stimulation. A standard 4-hour 51 Cr-release assay was used. Briefly, target cells were incubated with 51 Cr (100 mCi per 1 Â 10 6 cells) for 2 hours in a 371C water bath. Following incubation with 51 Cr, targets were washed three times with PBS, resuspended in RPMI-10% FBS and mixed with or without effector cells at the indicated effector-to-target ratios. In some experiments, tumor targets were incubated overnight with IFN-g. Assays were performed in triplicate for each sample at each ratio in 96-well round-bottomed plate. After 4 hours incubation, supernatants were harvested and the amount of 51 Cr released was measured by liquid scintillation counting. Percent-specific lysis was calculated hTERT gene pulsed DCs induce tumor-specific CTL response M Frolkis et al according to the following formula: [(experimental release-spontaneous release)/(maximum releaseÀsponta-spontaneous release)] Â 100.
Statistics
Percent-specific lysis values are expressed as mean7SEM.
Results
Phenotypic characterization and reconstitution of telomerase activity of monocyte-derived DC DCs isolated from human peripheral blood monocytes displayed a veiled morphology. While no CD14 antigen was detected on these cells, DCs expressed high levels of HLA-DR, CD86, and CD11C antigens. RT-PCR results clearly show that DCs express the telomerase RNA component, known as hTR (Fig 1a) . However, the mRNA corresponding to the catalytic component of the telomerase complex was undetectable in all but one DC preparation. To preclude the presence of contaminating activated lymphocytes, DCs were enriched by magnetic bead depletion of T and B cells using anti-CD3 and anti-CD19 antibodies. FACS analysis of the scatter profile before and after purification of one DC preparation is shown in Figure 1b . RNA obtained from two purified DC samples indeed showed the presence of hTR but not hTERT (Fig 1a) . This is consistent with the absence of telomerase activity in DCs as confirmed by TRAP assay (data not shown).
Both plasmid DNA and adenoviruses were used to introduce telomerase DNA into peripheral blood monocyte-derived DCs. DCs were transfected with hTERT containing pGRN 145 plasmid DNA (Fig 2a) using the cationic liposome DOTAP. TRAP analysis of samples collected 4 days after transfection demonstrated that DCs transfected with hTERT DNA possessed telomerase activity, while the control plasmid (pBBS212)-transfected cells were negative (Fig 2a) .
It has been shown that adenovirus transduction is an efficient method for transgene expression in DCs and results in higher levels of gene expression compared to plasmid DNA transfection. A map of the Ad-5-based recombinant, replication-defective virus containing the hTERT coding sequence is shown in Figure 2b . This AdhTERT vector was used to introduce the telomerase gene into 10 DC cultures from normal HLA-A2-positive donors. Telomerase activity was reconstituted in all 10 DC samples, and the TRAP result obtained from one representative DC sample is shown in Figure 2b . Reconstitution of telomerase activity appeared to follow a doseresponse of adenoviral infection. Telomerase activity was detected with an MOI of 10, and the activity continued to increase to 1.8-fold at 30 MOI, as determined by TPG analysis, at which point saturation level was attained. hTERT gene pulsed DCs induce tumor-specific CTL response M Frolkis et al TPG analysis was performed from TRAP gels that were run with 1000 cell equivalents (Fig 2b) . No telomerase activity was detected when DCs were left untransduced or transduced with AdGFP construct (Fig 2b and data not  shown) .
Localization of telomerase protein in AdhTERTtransduced DC At 3 days after AdhTERT transduction, DCs were subjected to immunofluorescence staining using an antihTERT peptide antibody, KM-2311. Nuclei were localized using the DNA binding dye, Hoechst 33412. Results presented in Figure 3 show that the telomerase protein is expressed and is predominantly localized in the nucleus and, to a lesser extent, in the cytoplasm of these cells. As expected, no staining was observed with anti-hTERT antibody at 0 MOI or with an isotype-matched control antibody. Preincubation of the anti-hTERT antibody with the corresponding telomerase peptide fragment abolished the signal, indicating the specificity of the antibody (Fig 3, upper panel, far right) .
Generation of telomerase-specific CTLs using hTERTtransfected DC
To determine if DCs transfected with hTERT DNA stimulate a T-cell response specifically directed to the telomerase antigen, CTL cultures were established from nine HLA-A2 donors. Bulk T-cell populations were incubated with irradiated hTERT transfected DCs at a ratio of 5:1 or 10:1. During the first and second stimulations, both CD4 and CD8 T cells were used so that DCs could process and present hTERT peptides in the context of MHC class I to CD8 cells and in the context of MHC class II to CD4 cells, respectively. Prior to the third stimulation, CD4 and NK cells were depleted by magnetic cell separation and the purified CD8 cells were stimulated with hTERT-transfected DCs. Five different tumor cell lines were used as CTL targets in these experiments. Three of these lines (SW403,143B, and MEL624) were high in telomerase activity whereas the remaining two lines (U2OS and SW1417) were found negative in TRAP assay (data not shown). Only three of nine hTERT plasmid-DNA-transfected DCs were able to generate telomerase-specific CTL response. Typical results of CTL analysis from one representative donor are presented. The CTLs were able to lyse telomeraseexpressing cell lines 143B and SW403 very efficiently, while the telomerase negative line SW1417 remained largely unaffected (Fig 4) . CTLs generated from the same donor, when primed with DCs transfected with the control plasmid, showed only background levels of activity against all three tumor targets. Using a different donor, it was determined that the hTERT-specific killing of SW403 cells could be enhanced by IFN-g treatment, which is known to increase the transcription of MHC molecules of the targets, while no specific lysis was detected against HLA-A2+, telomerase negative cell line, U2OS (data not shown). It should be mentioned that in two of the three DC samples that were effective in 
(b) Strong telomerase activity observed in DCs after AdhTERT infection at different MOIs (indicated on the figure). A diagram of the AdhTERT vector in which telomerase is under the control of CAG promoter is shown at the top part of panel (b)
. Uninfected DCs (0 MOI) did not exhibit telomerase activity as determined by TRAP assay. As expected, telomerase activity was abolished after heat inactivation.
hTERT gene pulsed DCs induce tumor-specific CTL response M Frolkis et al generating hTERT-specific CTLs, after hTERT DNA transfection, telomerase activity was reconstituted, albeit lower than that observed with AdhTERT transduction (Fig. 2a) . Nevertheless, in both instances, significant lysis was observed with hTERT-specific CD8+ T cells against different tumor targets suggesting that DCs reconstituted with telomerase gene were effective in raising antigenspecific CTL response.
AdhTERT-transduced DCs also generate anti-tumor CTLs in vitro
As mentioned above DCs from 10 HLA-A2-positive donors were transduced with 30 or 100 MOI of the AdhTERT or AdGFP vector. All AdhTERT-transduced DCs were positive for telomerase activity and nine of 10 DC samples were able to generate CTL response in vitro.
hTERT-specific CTL results from two donors are presented in Figure 5 (a and b). As shown in Figure 5a , CTLs from one donor exhibited higher lysis against telomerase-positive 143B osteosarcoma cells and MEL 624 melanoma cells compared to telomerase-negative U2OS cell line. CTLs from a different donor resulted in causing greater than 40% lysis of SW403 targets at an E:T ratio of 30:1 as compared to the 10% lysis using AdGFPtransduced control DCs. Taken together, these results indicate that AdhTERT-transduced DCs are capable of generating specific CTLs against telomerase-positive tumor cell lines from different tissue origins.
To determine the relative proportion of hTERTspecific CTLs and adenoviral antigen-specific CTLs, 143B cells were transduced with AdhTERT or AdGFP constructs at 100 MOI and used as target cells. CTLs generated using AdhTERT-transduced DCs (100 MOI) were directed to lyse AdhTERT-infected 143B cells, while CTLs generated with AdGFP-transduced DCs (100 MOI) were used to lyse AdGFP-infected 143B cells. CTLs directed against AdhTERT exhibited 85% lysis at an E:T ratio of 50:1, while about 50% lysis was observed with AdGFP-specific CTLs against respective targets (Fig 6) . To further assess the specificity of the CTL response, a 10-fold excess of cold AdGFP-transduced 143B cells were added to the 51 Cr-labeled 143B target cells. Results presented in Figure 6 showed approximately 55% drop in the AdhTERT/DC-stimulated CTL activity (E:T ratio of 50:1) when the cold targets were used. Since no GFPspecific CTLs were present in AdhTERT/DC-stimulated CTL cultures, competitive inhibition observed with cold AdGFP-143B cells was attributable to telomerase and adeno-specific T cells. Similarly, addition of cold AdGFP-infected 143B cells reduced the CTL activity generated with AdGFP-transduced DCs to a level that was equivalent to that of hTERT-specific CTLs observed in the presence of cold targets (Fig 6) . From these data, it appears that approximately 35% of the lytic activity was directed against hTERT epitopes, while between 20 and 25% of the activity was specific for adenoviral antigens in DC/AdhTERT primed CTL cultures. 
Specificity of CTLs directed against hTERT
To further confirm the specificity of the CTLs, we took the advantage of the HLA-A2 positive, telomerase negative cell line, U2OS. U2OS cells were transduced with AdhTERT virus at 100 MOI, and 48 hours after infection these cells were stained for hTERT protein using KM-2311 antibody (Fig 7a) . While the telomerase protein was not detectable in untransduced cells (Fig 7a, upper  left) , virtually all cells were hTERT positive after adenoviral transduction (Fig 7b, upper right) . However, it should be pointed out that the telomerase-expressing U2OS cells lacked enzymatic activity, which suggests that telomerase RNA component is missing. Absence of hTR transcripts in U2OS cells was corroborated by RT-PCR analysis. CTLs were generated using AdhTERT-transduced DC population generated from a normal HLA-A2-positive PBMC sample. After three stimulations, CTL activity of the purified CD8 population was tested against unmodified, AdGFP-or AdhTERT-transduced U2OS cells. While some CTL activity was specifically directed against adenoviral antigens, maximum lysis was observed in U2OS cells expressing telomerase protein (Fig 7b) . Virtually, no lysis was detected in unmodified U2OS cells. These results clearly demonstrate that the majority of CTLs were targeted specifically against telomerase peptides that were presented in the context of HLA-A2 by AdhTERT-modified tumor cells.
Discussion
Telomerase activity is upregulated in a great majority of human tumors mostly because of an increase in the rate of transcription of hTERT gene that encodes for the T cells from donor 2 were stimulated with AdhTERT-infected or AdGFP-infected DCs; the latter was used as negative control. Telomerase-expressing SW-403 cells were used as targets for both TERT-specific and GFP-specific CTLs generated in vitro. Effector:target ratios presented in the x-axis while the y-axis represent percent specific lysis. Telomerase-negative U2OS cell line was used as negative control for both donors. Similar results were observed with five different donors.
hTERT gene pulsed DCs induce tumor-specific CTL response M Frolkis et al catalytic subunit of the enzyme. 13 Therefore, telomerase has been implicated as a universal tumor antigen for many types of malignancies. On the other hand, gene and immunotherapeutic strategies can have broader clinical applications if the target antigen is expressed in a wide range of cancer. The evidence that HLA-A2-restricted telomerase peptides are presented by a variety of tumors has recently been documented by two independent groups. Using DCs or PBMCs that were pulsed with hTERT peptides, these investigators have generated potent CTL response in vitro from normal individuals as well as from cancer patients. 14, 15 In collaboration with Eli Gilboa, we have demonstrated that DCs pulsed with hTERT RNA could also give rise to antitelomerasespecific CTLs, which specifically lysed autologous tumor cells. 16 In this study, we have used both plasmid DNA and an E1-, E3-deleted adenoviral vector containing the hTERT gene under the CAG promoter. Although transfection of DCs with DNA or RNA complexed with various liposomal formulations has achieved some success, adenoviral transduction is probably the most effective way to introduce new genes into these cells. Several groups have demonstrated that both human and murine DCs can be efficiently infected with adenoviral vectors designed to express various TAAs. [24] [25] [26] Our results on hTERT DNA transfection versus AdhTERT transduction of human DCs corroborated these findings.
While only two of nine DC samples were successfully transfected with plasmid DNA, all 10 samples were well transduced with the adenoviral vector resulting in enzymatic activity. Furthermore, a majority of the AdhTERT/DC samples were able to stimulate more robust telomerase-specific CTL response against various tumor targets in vitro. Based on these results, it is tempting to speculate that recombinant adenoviral constructs containing hTERT gene is a promising vector for telomerase-based immunotherapy of cancer. However, the ability to use plasmid DNA to generate a TERTspecific CTL indicates that this form of vaccination should also be considered in the case where the potential adenovirus toxicity or high level of neutralizing antibodies is a concern.
Vonderheide et al 14 have demonstrated that in order to induce an hTERT-peptide-specific CTL response, DCs are not required to have detectable telomerase. Data presented in this study show that hTERT-DNA-transfected or AdhTERT-infected DCs become functionally telomerase positive. In fact, two of three hTERT-DNAtransfected DC samples that generated CTL responses were also positive by TRAP assay (Fig 2a and data not  shown) . Similarly, all AdhTERT-transduced DC samples eliciting strong CTL stimulation had telomerase activity. These observations suggest that telomerase activity in DNA, RNA, or adenovirus-modified DC samples from cancer patients may be of importance in predicting the outcome of hTERT/DC-based immunotherapy of cancer.
Similar to the findings reported by Nair et al 16 using in vitro transcribed TERT RNA, we present evidence that DCs can process hTERT proteins that ultimately lead to the expression of HLA-A2-restricted peptides after introducing the telomerase gene. In particular, AdhTERT-transduced DCs probably have the potential advantage of expressing a variety of known 14, 15 and yet unidentified hTERT-derived antigenic epitopes on the cell surface in conjunction with MHC molecules. We have observed some CTL activity against adenoviral antigens when DCs were transduced with AdGFP construct. The observed background activity may be because of low levels of adenoviral gene transcription and protein synthesis after the removal of E1 transactivators and the E3 regulatory genes or because of the expression of GFPderived antigenic peptides. However, in all cases, hTERTspecific CTL response was considerably higher (two to three fold) than those observed with either adenoviral or GFP antigen (Fig 7) .
Much effort has been made to identify novel TAAs from various types of cancer, success of these attempts remained limited at best. Based on the results presented in this paper and earlier publications, it appears that telomerase peptides are presented in the context of class I MHC by a wide variety of solid tumors and tumors of hematological origin. In order to show that telomerase can be used as a universal tumor antigen, we chose three telomerase-positive well-characterized tumor cell lines of diverse tissue origins. The osteosarcoma cell line, 143B, that is highly positive for telomerase antigen, and to our Figure 6 Inhibition of CTL response against hTERT and adenoviral antigens by cold target addition. HLA-A2+ DCs transduced with AdhTERT or AdGFP vector were used to generate CTLs in vitro as detailed in Materials and methods. Cytotoxicity assay was performed with AdhTERT-or AdGFP-infected 143B tumor cells as targets for the corresponding CTL populations (described in the inset). For competition assay, 10-fold excess of cold AdGFP-infected 143B cells was added to the CTL effectors prior to adding 51 Cr-labeled 143B cells.
hTERT gene pulsed DCs induce tumor-specific CTL response M Frolkis et al knowledge, does not express any other known tumor antigen, while Mel624 is a melanoma cell line, which is known to express a well-characterized tumor antigen, MART-1. 45 In addition, SW403, a colon carcinoma cell line, is known to express another cancer antigen, CEA1. 46 Using telomerase-gene-transfected DCs, we determined that the hTERT-specific CTLs were able to specifically lyse these three telomerase-positive cell lines of different tissue types. These findings lend support to the fact that telomerase is a pan tumor antigen that may have a very wide application for cancer vaccination. 15, 16 Inclusion of telomerase gene or telomerase-derived peptides with other well-characterized cancer antigens such as CEA, MART-1, or PSA in the vaccination regimen might elicit more powerful antitumor immunity in vivo.
Although telomerase expression is largely restricted to cancer cells, certain hematopoietic progenitor cells, activated lymphocytes, and tissue-specific stem cells in the skin and intestinal tissues and germ cells are known to possess telomerase activity. [47] [48] [49] [50] [51] Consequently, any hTERT-based cancer vaccine therapy will have to assess the potential side effects associated with autoimmunity to cells and organs that are telomerase positive. Encouraging results published from two independent groups show that hTERT-peptide-specific HLA-A2-restricted CTLs were unable to kill telomerase-positive autologous CD34+ hematopoietic stem cells from normal donors or from cancer patients. 14, 15 These CTLs, however, were very effective in causing lysis of telomerase-positive cancer cell targets. It is conceivable that the level of telomerase expression in normal cells is below the threshold needed for recognition by these TERT peptide-specific CTL populations. Whether such a scenario is applicable for CTLs that are generated by transducing DCs with the full-length telomerase gene is unclear at this time. Ongoing phase I clinical studies with hTERT genemodified DC vaccination should address the issue of autoimmunity in vaccinated cancer patients.
The promoter region of human telomerase has been cloned and characterized. [52] [53] [54] Consistent with the higher Figure 7 Antigenic specificity of CTLs generated by AdhTERT-transduced DCs. (a) Telomerase-negative U2OS cells were infected with AdhTERT virus at 100 MOI and 48 hours after infection hTERT expression was determined by immunofluorescence using KM2311 antibody (upper right panel). Uninfected U2OS cells were also stained with KM2311 to determine background fluorescence (upper left panel). (b) CTLs generated using AdhTERT-transduced DCs were tested for cytotoxicity against unmodified U2OS (background lysis), AdGFP transduced U2OS (adenoviral antigen specific lysis) and AdhTERT transduced U2OS to delineate the difference between hTERT-specific versus adeno-specific lysis.
hTERT gene pulsed DCs induce tumor-specific CTL response M Frolkis et al levels of telomerase activity in cancerous but not normal cells, the hTERT promoter is active virtually in all types of tumors. By subordinating the herpes simplex virus thymidine kinase (HSV-TK) suicide gene under the control of a 204-bp fragment of hTERT promoter, we have been able to restrict the TK expression to tumor cells. 55 Intratumoral administration of an adenoviral vector containing hTERTp-TK construct into telomerase-positive human tumor xenografts in nude mice and subsequently followed by ganciclovir (GCV) treatment resulted in tumor regression. 55 These findings along with the results described in this manuscript and those published earlier [14] [15] [16] suggest that the human telomerase gene and its promoter may have useful application for cancer therapy.
